222 related articles for article (PubMed ID: 28337317)
41. Synthesis and Biological Evaluation of JAHAs: Ferrocene-Based Histone Deacetylase Inhibitors.
Spencer J; Amin J; Wang M; Packham G; Alwi SS; Tizzard GJ; Coles SJ; Paranal RM; Bradner JE; Heightman TD
ACS Med Chem Lett; 2011 May; 2(5):358-362. PubMed ID: 21572592
[TBL] [Abstract][Full Text] [Related]
42. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.
Imesch P; Dedes KJ; Furlato M; Fink D; Fedier A
Int J Oncol; 2009 Sep; 35(3):631-40. PubMed ID: 19639184
[TBL] [Abstract][Full Text] [Related]
43. Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
Suzuki T; Kouketsu A; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N
Bioorg Med Chem Lett; 2004 Jun; 14(12):3313-7. PubMed ID: 15149697
[TBL] [Abstract][Full Text] [Related]
44. Design and synthesis of novel histone deacetylase 6 inhibitors with benzyl-triazole as the core skeleton.
Mou Z; Gao J; Miao H; Zhang L; Su L; Wang B; Luan Y
Biosci Trends; 2019 Jul; 13(3):267-272. PubMed ID: 31155552
[TBL] [Abstract][Full Text] [Related]
45. SAHA-based novel HDAC inhibitor design by core hopping method.
Zang LL; Wang XJ; Li XB; Wang SQ; Xu WR; Xie XB; Cheng XC; Ma H; Wang RL
J Mol Graph Model; 2014 Nov; 54():10-8. PubMed ID: 25241128
[TBL] [Abstract][Full Text] [Related]
46. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
[TBL] [Abstract][Full Text] [Related]
47. 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.
Huong TT; Dung do TM; Oanh DT; Lan TT; Dung PT; Loi VD; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB; Nam NH
Med Chem; 2015; 11(3):296-304. PubMed ID: 25256241
[TBL] [Abstract][Full Text] [Related]
48. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
Jeon HS; Ahn MY; Park JH; Kim TH; Chun P; Kim WH; Kim J; Moon HR; Jung JH; Kim HS
Int J Oncol; 2010 Aug; 37(2):419-28. PubMed ID: 20596669
[TBL] [Abstract][Full Text] [Related]
49. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents.
Ververis K; Hiong A; Karagiannis TC; Licciardi PV
Biologics; 2013; 7():47-60. PubMed ID: 23459471
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
Reßing N; Marquardt V; Gertzen CGW; Schöler A; Schramm A; Kurz T; Gohlke H; Aigner A; Remke M; Hansen FK
Medchemcomm; 2019 Jul; 10(7):1109-1115. PubMed ID: 31391882
[TBL] [Abstract][Full Text] [Related]
51. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
52. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
53. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
Kelly WK; Marks PA
Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
[TBL] [Abstract][Full Text] [Related]
54. (7-Diethylaminocoumarin-4-yl)methyl ester of suberoylanilide hydroxamic acid as a caged inhibitor for photocontrol of histone deacetylase activity.
Ieda N; Yamada S; Kawaguchi M; Miyata N; Nakagawa H
Bioorg Med Chem; 2016 Jun; 24(12):2789-93. PubMed ID: 27143132
[TBL] [Abstract][Full Text] [Related]
55. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
[TBL] [Abstract][Full Text] [Related]
56. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
58. A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor.
Hanif M; Arshad J; Astin JW; Rana Z; Zafar A; Movassaghi S; Leung E; Patel K; Söhnel T; Reynisson J; Sarojini V; Rosengren RJ; Jamieson SMF; Hartinger CG
Angew Chem Int Ed Engl; 2020 Aug; 59(34):14609-14614. PubMed ID: 32431061
[TBL] [Abstract][Full Text] [Related]
59. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.
Zhang S; Huang W; Li X; Yang Z; Feng B
Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653
[TBL] [Abstract][Full Text] [Related]
60. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.
Bieliauskas AV; Weerasinghe SV; Pflum MK
Bioorg Med Chem Lett; 2007 Apr; 17(8):2216-9. PubMed ID: 17307359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
